1. Emcure’s Initiatives in Anemia Management
Dr. P. Bhandari, M.D.

2. We bring difference in lives
Emcure
Research driven pharmaceutical company
Responsible corporate citizen
giving back to society from which it profits
Therapeutic areas
Anemia
AIDS
Cardiology
Nephrology
Oncology
Gynecology
Diabetes
Neurology
Orthopedics
Gastroenterology
We bring difference in lives

3. Anemia – a global problem
According to a survey conducted by NFHS, the prevalence of anaemia in young girls aged between years is 56% with higher rates in rural than in urban India.

4. Anemia affects all Mother Child Pre-term delivery
Fetal and maternal mortality
Low birth weigh baby
Child
Impaired mental function
Increased infections
Frequent diarrhea

5. Anemia – signs/symptoms
Fatigue (very common)
Weakness (very common)
Dizziness
Shortness of breath
Irritability
Lack of concentration
Pale skin and tongue
Brittle nails
Low hemoglobin
Iron deficiency anaemia with depapillated tongue, depigmentation of the upper lip and epithelial erosion of the lower lip

6. Emcure in Anaemia management
Innovative oral iron products:
Ferrous ascorbate tablets, suspension, etc.
State of the art parenteral iron products:
Iron sucrose injection
Ferric carboxymaltose injection
Biotechnology products:
Erythropoietin

7. Ferrous Ascorbate Leaders in the ferrous ascorbate market
Offering own R&D ferrous ascorbate
Granted Indian Patent
The best oral iron so far:
Maximum bioavailability of up to 43%
Excellent tolerability
Prevents inhibitory action of dietary phytates etc
Proven safety and efficacy
Dose: 100 mg elemental iron daily for adults

8. Why Ferrous Ascorbate?
Inhibitors
Facilitators
The absorption of iron from ordinary iron supplements is approximately 10% or less
This is due to presence of inhibitory ligands like phytates, tannins, phosphates etc in food
The presence of ascorbate facilitates absorption by preventing the action of these inhibitory ligands
This increase absorption of iron from ferrous ascorbate up to 43%

9. When oral iron may not be sufficient?
In severe anemia that will require very long time to correct
Very low iron stores that need quick replenishment
In renal failure patients who do not respond to oral iron
In menorrhagia-associated severe iron-deficiency anemia
In anemia associated with cancer
 Parenteral (IV) iron

10. Iron Sucrose Injection
The dominant IV iron for anaemia management
Does not have risk of dextran-induced hypersensitivity
Used by both nephrologists and obstetricians
Dose: 100 mg by slow IV bolus x max thrice weekly, or mg IV infusion x max thrice weekly, to replenish cumulative deficit

11. Ferric Carboxymaltose Injection
The latest IV iron
Introduced first in India by Emcure
Offers feasibility of total dose infusion of 1g in 15 min
No dextran-type hypersensitivity
Safe & effective in different indications

12. Erythropoietin
Manufactured in Gennova Biopharmaceuticals facility of Emcure
Matching European Pharmacopoeia standards
Used by nephrologists in renal anemia
Used by obstetricians in EPO-deficient IDA in pregnancy

13. FOGSI – Emcure Social Responsibility

14. Emcure’s Corporate Social Responsibility

15. Emcure’s Corporate Social Responsibility

16. Emcure’s Corporate Social Responsibility

17. Emcure’s Corporate Social Responsibility

18. FOGSI-Emcure Publications

19. Emcure in Anemia Management
Latest research and development
Quality products
Education, awareness and support
through CSR activities
We bring difference in lives

20. Emcure’s websites